Vaxeal has created a large EU and African consortium for the development of a new generation of pan-ebola vaccines
Vevey, January 4, 2015: Vaxeal has created a large EU and African consortium comprising 14 different private and public institutions for the development a new generation of vaccines that provide protection against all major Ebola strains (pan-Ebola vaccine).The World Health Organization has announced that Ebola is now one of the most dangerous diseases to threaten the human race on a global scale. The severity of the recent outbreak of Ebola in Western Africa has reached historic proportions and underscores the vulnerability of populations worldwide to pathogens. Outbreaks of Ebola virus (EBOV) disease have occurred in Africa in the past, however, the current epidemic caused by the Zaire Ebola virus (ZEBOV) has been characterized by much greater numbers of reported cases with a more rapid spread geographically than ever before. The ZEBOV virus has killed more people than all the previous epidemics combined since 1976.
About VaxealCreated in 2009, Vaxeal Holding SA is an SME headquartered in Vevey (Switzerland). The company, in partnership with leading International Research Institutes, is developing therapeutic vaccines in combination with immuno-modulatory drugs for the treatment of cancers and infectious diseases. The cutting-edge immunotherapies are protected by several patent families. Our initial programs have reached the pre-clinical stage in major disease segments, and are expected to enter into clinical trials in Europe in 2016. Vaxeal is member of Vaccines Europe, and the European Biopharmaceutical Enterprises. The company received a special MIT award for “its remarkable breakthrough in the field of vaccines”.